Pfizer
US CDC will not publish report showing COVID vaccine effectiveness
"Scientific reports are routinely reviewed at multiple levels to ensure they meet the highest standards before publication," said HHS spokesperson Andrew Nixon.
'When I grow up, I want to be like you': remembering Morris Kahn's most productive years - opinion
Grapevine, November 30, 2025: Mamdani complexities
MBS’s first Washington trip since 2018 brings new investments
Was the fourth dose of Pfizer's COVID vaccine effective? -study
An extensive Israeli study of 24,088 elderly recipients living in long-term-care geriatric facilities found that the fourth dose saved many lives.
Pfizer's Paxlovid reduces COVID risk in seniors regardless of vaccine status -study
Use of Pfizer's pills, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared in the United States.
Pfizer COVID-19 vaccine prevented almost 700,000 hospitalizations -study
The study also found that the vaccine saved over $30 billion in US healthcare costs and over $40 billion in lost productivity.
COVID-19 booster shot significantly boosts efficacy - study
The estimated vaccine effectiveness of the third dose against PCR-confirmed infection stood at 85.6% compared to the two doses, Sheba researchers found.
Pfizer says COVID-19 drug Paxlovid fails to prevent infection of household members
The trial enrolled 3,000 adults who were household contacts exposed to an individual who was experiencing symptoms and had recently tested positive for COVID-19.
I got COVID-19, but Paxlovid saved my life - opinion
I don’t know if it was the Paxlovid or if my immune system is working as it’s supposed to, but within five days, my symptoms started to subside.
FDA green lights second COVID-19 booster shot for older Americans
Pfizer and BioNTech originally asked for the next booster doses to be authorized for people 65 and older in a submission citing data collected in Israel.
Generic drugmakers sign on to make cheap version of Pfizer COVID-19 pill
Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries.
COVID-19: First trial outside US for Omicron vaccines kicks off
The study will evaluate the safety, tolerability and immunogenicity of a higher dose of the Pfizer-BioNTech COVID-19 vaccine as well as the experimental Omicron vaccine.
Israeli startup CytoReason collaborates with Pfizer on machine learning
CytoReason’s massive database and AI-led platform, biotech companies can identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of approval.
